Kornimate/medical-research-clean huggingface dataset:
prognostic value of spect-ct quantitative indices for the response assessment of bone metastatic prostate carcinoma

Conditions: Prostate Cancer

Summary: prognostic interest of bone scintigraphy in bone metastatic prostate carcinoma (bmpc) has been shown. recent technological advances allow to perform quantitative bone spect-ct in routine practice. the aim of this study is to assess the prognostic interest of quantitative bone spect-ct in bmpc.

prostate adenocarcinoma is one of the most common cancer in men, and bone its most frequent distant metastasis location. 5-year survival has greatly increased these last two decades, with wide differences between countries. nevertheless, the prognosis of castrate-resistant bone metastatic prostate cancer (bmpc) remains poor. pcwg (prostate cancer working group) 2 has proposed in 2007 criteria to evaluate response to treatment for prostate cancer. there are based on composite data, including clinical signs (such as general condition and bone pain), prostatic specific antigen (psa) variation, ct scan (recist criteria) and bone scan. the scintigraphic part is based on whole body planar acquisition, and on the assessment of new uptakes. these bone scan criteria are simplistic, because only a visual analysis is possible, without consideration of changes in intensity. moreover, these criteria consider the bone scan as a planar imaging, and it has been shown that single photon emission computed tomography (spect) improved sensitivity, specificity, positive and negative predictive values in oncologic context. finally, "pcwg2 (prostate cancer working group 2) recognizes that there are no validated criteria for response on radionuclide bone scan". to reflect bone metastasis burden, a quantitative analysis method for bone scintigraphy, the bone scan index (bsi), had been tested. bsi is based on the uptake of whole body planar imaging. while baseline bsi seemed to offer a poor correlation with overall survival (os), on-treatment changes in bsi appeared to be a decent response marker. but a volumetric quantitative biomarker may improve the accuracy of this assessment. the recent development of a new spect quantification tool (xspect quant® tool, siemens) could offer good performances on therapeutic assessment. the objective of this study is to assess the interest of this new quantitative volumetric method in bone scan response evaluation of bmpc.

Eligibility criteria:
inclusion criteria: patients who underwent a bone spect-ct (symbia intevo t6) between april 2014 and april 2017, with bone metastatic prostate cancer. no opposition of the patient to participate in the study. exclusion criteria: opposition of the patient. age\<18 y/o

Keywords: bone scintigraphy quantification prostate cancer prognosis
non-invasive brain stimulation

Conditions: Stroke

Summary: the study focusses on utilizing neuroimaging modalities, including electroencephalography (eeg) and functional magnetic resonance imaging (fmri) to study the impact of non-invasive brain stimulation on the prefrontal cortex during a cognitive task.

in this study, a total of 40 subjects will be randomly assigned to 2 groups i.e. experimental and sham. conventional transcranial direct current stimulation (c-tdcs) and high-definition transcranial direct current stimulation (hd-tdcs) will be used to stimulate the prefrontal cortex of the brain. eeg and fmri will be collected before, during and after stimulation to understand the impact of stimulation on brain dynamics. the investigators hypothesize that the stimulation of the prefrontal cortex will improve performance during cognitive tasks along with changes in the neural processing detected by neuroimaging modalities.

Eligibility criteria:
inclusion criteria: * right handedness, * age \> 18 exclusion criteria: * history of any other neurological disease, * any psychological or psychiatric disease, * significant visual or auditory impairments, * tdcs contraindications including implanted metallic or electronic devices, seizures or convulsions, and pregnancy.
metabolomic fingerprint after bariatric surgery

Conditions: Obesity

Summary: background: obesity is associated with multiple diseases. bariatric surgery is the most effective therapy for severe obesity that cannot only reduce body weight but also obesity-associated morbidity. objective: the metabolic alterations associated with obesity and respective changes after bariatric surgery are incompletely understood. design: in the longitudinal observational study, the investigator applied a 1h-nmr-based global, untargeted metabolomics strategy on human serum samples that were collected before and repeatedly up to one year after distinct bariatric procedures (sleeve gastrectomy, proximal and distal roux-en y gastric bypass; rygb). for comparison, the investigator also analyzed serum samples from normal-weight and less obesity obese subjects that were matched for 1-year postoperative bmi values of the surgical groups.


Eligibility criteria:
inclusion criteria: * bmi \>/=35 kg/m2 * at least 2 years of unsuccessful conservative weight loss attempts exclusion criteria: * \< 18 years of age * bmi \< 35 kg/m2 * informed consent was not signed by the patient

Keywords: metabolic alterations
comparison of total tubeless mini-pcnl versus tubeless mini-pcnl

Conditions: Surgery-Complications; Nephrolithiasis Staghorn Calculus; Safety Issues

Summary: limited literature has focused on the use of totally tubeless mini-percutaneous nephrolithotomy (mini-pcnl) for the treatment of large renal stones. this randomized controlled trial aims to compare complication and safety of mini-pcnl between total tubeless and tubeless mini-pcnl.

after being informed about study and potential risks, all patient giving written informed consent with undergo a mini-pcnl operation. patient who meet the eligibility requirements will be randomized in a single-blind manner (patient) in a 1:1 ratio to total tubeless mini-pcnl or tubeless mini-pcnl.

Eligibility criteria:
inclusion criteria: * patients diagnosed with kidney stones with a size ranging from 20 to 40 millimeters. * patients have undergone mini-pcnl, unilateral * absence of urinary tract infections before surgery. * no urological congenital abnormality * no coagulopathy exclusion criteria: * presence of residual stones after the surgery, fragments larger than 4 millimeters. * patients with a single functioning kidney * complicated cases, including: 1. massive bleeding in the upper tract during surgery 2. severe collecting systems injury during surgery 3. severe upj mucosa swelling considered unsafe by the physician, requiring the placement of a dj stent or nephostomy tube * participants who decline or request withdrawal from the research study.

Keywords: total tubeless pcnl complication safety tubeless pcnl
peripheral catheter pressure ulcer prevention in pediatry : use of compresses versus standard care

Conditions: Pressure Ulcer

Summary: peripheral venous catheterisation is a multi-daily practice in a paediatric ward. in our pediatrics department, nurses have observed for several years now the appearance of pressure sore-like skin lesions at the junction of the peripheral venous catheter with the extension tube. a ward habit has spontaneously developed of applying a compress under this junction. the objective is to minimize physical or emotional aggression as well as pain. pain that is denied or not identified and not relieved is memorized by the child, which can have consequences on the perception of pain and the subsequent acceptance of care. to date, through their reading and research, investigators have been able to find articles mentioning the risks of pressure ulcers in children related to medical devices. however, few elements are developed concerning catheter-related pressure ulcers, especially on this specific technique for preventing injuries at the catheter-extension tube junction. investigators have not found any recommendations on this subject. thus, the aim of this study is to compare two peripheral venous catheter fixation devices, with compress and without compress, and to analyse the frequency of pressure ulcer occurrence and the intensity of this lesion.


Eligibility criteria:
inclusion criteria: * aged 1 month to 18 years old, according to the criteria of the paediatrics department of the departmental hospital la roche sur yon . * hospitalized in paediatrics ward or consultant in paediatric emergencies with a high probability of being hospitalized in paediatrics ward later. * with an indication for the insertion of a short peripheral venous catheter * written agreement from the holder(s) of parental authority exclusion criteria: * children with dermatological affections prior to inclusion and at the puncture site (atopic dermatitis, skin infection, skin wound, chickenpox, epidermolysis bullosa) * allergy to fixation devices * known immune deficient child * refusal of the patient or of the holders of parental authority to participate * life-saving emergency care * patient already included in the study * patient without social security coverage

Keywords: pediatrics pressure ulcer peripheral venous catheter
first-time-in-human (ftih) study to evaluate the safety, tolerability and pharmacokinetics (pk) of vh4004280 in healthy participants

Conditions: HIV Infections

Summary: this ftih study aims to evaluate the safety, tolerability and pk of the novel investigational human immunodeficiency virus (hiv)-1 capsid inhibitor vh4004280 in healthy adults. the study will be conducted in 3 parts: part 1 will investigate single ascending doses (sad), part 2 will investigate multiple ascending doses and drug-drug interaction (mad/mad ddi) part 3 will investigate single dose relative bioavailability (rba) of a new formulation of vh4004280.


Eligibility criteria:
inclusion criteria: * participant must be 18 to 55 years of age inclusive. * participants who are overtly healthy. * male or female participants of non-childbearing potential. * capable of giving signed informed consent. exclusion criteria: * history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, neurological or psychiatric disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study drug or interfering with the interpretation of data. * abnormal blood pressure. * symptomatic herpes zoster. * evidence of active or latent tuberculosis (tb). * lymphoma, leukemia, or any malignancy within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years. * breast cancer within the past 10 years. * current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of gilbert's syndrome or asymptomatic gallstones). * qt interval corrected for heart rate according to fridericia's formula (qtcf) greater than (\>)450 milliseconds (msec). * past or intended use of over-the-counter or prescription medication including herbal medications. * live vaccine(s) within 1 month prior to screening or plans to receive such vaccines during the study. * exposure to more than 4 new investigational products within 12 months prior to the first dosing day. * current enrollment or past participation in another investigational study. * alt \>1.5 times upper limit of normal (uln), total bilirubin \>1.5 times uln, and/or estimated serum creatinine clearance less than 60 milliliters per minute. * history of or current infection with hepatitis b or hepatitis c. * positive severe acute respiratory syndrome coronavirus 2 (sars-cov-2) test, having signs and symptoms, or having contact with known coronavirus disease-2019 (covid-19) positive person/s. * positive hiv antibody test. * user of tobacco or nicotine-containing products, regular alcohol consumption and/or regular use of known drugs of abuse. * sensitivity to the study drug, or components thereof.

Keywords: first-time-in-human gsk4004280 vh4004280 hiv-1 capsid inhibitor single ascending doses multiple ascending doses
mostafa maged maneuveur to prevent and control post-partum haemorrhage during normal vaginal delivery

Conditions: Post Partum Hemorrhage

Summary: pph is commonly defined as blood loss exceeding 1000 milliliters after vaginal birth or cesarean section.1 pph is often classified as primary/immediate/early (occurring within 24 hours of birth) or secondary/delayed/late (occurring from more than 24 hours postbirth to up to 12 weeks postpartum).. atonic post-partum haemorrhage is one of the most challenging complications of normal delivery process . there are many maneuveurs applied to the atonic uterus for controlling the blood loss and conserving the uterus from hysterectomy process . there are pharmacological and surgical methods to control the bleeding . in this study , mostafa maged technique is to prevent and control post-partum bleeding during vaginal delivery . it is so simple and not-costly method .

in this study , mostafa maged technique to prevent and control post-partum bleeding during vaginal delivery . it is so simple and not-costly method . mostafa maged maneuveur has been applied to those all female patients to prevent or control post-partum bleeding in normal delivery . mostafa maged technique is applied by :- (description of the mostafa maged technique) :- 1. first , placing the right hand to the posterior fornix of vaginal canal trying to cuddle the lower part of uterus compressing the anterior and posterior walls of the uterus . 2. second , placing the left hand over the fundus of the uterus and the posterior wall of uterus from the abdominal part of the pregnant mother ( the side of the abdominal skin ) . 3. third , by the two hands , trying to grasp the whole uterus by the two hands abdominally and vaginally against the symphysis pubis as if the uterus is cuddling the symphysis pubis bone and in this way , getting the anterior and posterior walls of the uterus against each other compressed is achieved and reducing the intra-cavitary space so prevention of the expansion of the uterus is applied .

Eligibility criteria:
inclusion criteria: * pregnant females inclusion criteria :- 1. all pregnant patients 2. age is between (18) to (40) years old exclusion criteria: 1. smokers 2. morbid obese 3. medical history of blood diseases and collagen diseases

Keywords: mostafa maged maneuver atony normal delivery postpartum bleeding
rehabilitation after coronary bypass grafting. comparison of different types of rehabilitation programs

Conditions: Coronary Artery Disease

Summary: the purpose of this study is to compare different types of rehabilitation after coronary bypass surgery. the investigators wish to compare rehabilitation in an institution for four weeks with a home based rehabilitation. they also wish to compare rehabilitation in an institution for four weeks with a rehabilitation program were the patients live at home but visit the hospital twice a week for twelve week. the investigators will measure the patients' physical capacity by measuring their maximal oxygen consumption. the investigators will also analyze their blood and their endothelian function (how well their arteries dilate).


Eligibility criteria:
inclusion criteria: * coronary artery bypass exclusion criteria: * significant lung disease * drug abuse * pregnancy * major physical impairment

Keywords: coronary artery bypass [e04.100.376.719.332]
age-related cognitive change of femur

Conditions: Osteoporosis

Summary: age-related change of femur is not well-known. the investigators investigated the longitudinal changes of femur.

recently, bisphosphonate-related atypical fracture of femur (aff) is paid attention in clinicians. almost all affs were occurred in thicker cortical thickness. but age-related change of femur is not well-known. the main objective of this study is to reveal the age-related change of femur.

Eligibility criteria:
inclusion criteria: * osteoporosis or osteopenia patients who presented to our hospital exclusion criteria: * patients without osteoporosis or osteopenia

Keywords: cortical thickness age
a study to evaluate the efficacy and safety of meptin® swinghaler® and ventolin® mdi in stable asthma patients

Conditions: Asthma

Summary: this is an open-label, randomized, cross-over, active-controlled study to evaluate the efficacy and safety effects using meptin® swinghaler and ventolin® mdi in stable asthma patients.


Eligibility criteria:
inclusion criteria: 1. male or females outpatients aged ≥ 16 years old with stable mild to moderate persistent asthma; stability was assessed the patient remained in the same severity class (mild, moderate) and had no acute exacerbations by investigator judgment during the past 14 days; 2. pulmonary function test: * improvement ≥12% reversibility in fev1 or fvc following administration of an inhaled β2-agonist before the study or ; * positive result of broncho-provocation test (pc20 ≤ 32 mg/ml) before the study. 3. baseline forced expiratory volume in one second 60% ≤(fev1)≤ 90% of predicted value on entry of the study; exclusion criteria: 1. hypersensitivity to β2-agonist or lactose; 2. hospitalization due to asthma during the previous 3months; 3. respiratory tract infection requiring treatment with antibiotics in the previous 4 weeks; 4. oral or systemic corticosteroids in the previous 4weeks; 5. inadequately controlled hyperthyroidism; 6. severe hepatic or renal or cardiovascular disease as judged by the investigator; 7. patients receive an investigational drug within 30 days prior to admission to the study; 8. patients with significant alcohol, drug or medication abuse as judged by the investigator; 9. females who are pregnant or breast-feeding; (exception: females of child-bearing age might be included, if in the opinion of the investigator, they are using adequate contraceptive precautions).
effect of physical activity on depressive symptoms with a 5 month follow-up

Conditions: Major Depressive Disorder

Summary: the main objective of this study is to evaluate the effect of a 12 weeks adapted physical activity program (active walking) on depression by analyzing the dynamics of emotional and cognitive functioning. the secondary objectives are to test the effects of a physical activity on functional performance and to highlight psychological mechanisms.

primary outcomes: self evaluations concerning global self-esteem, a perception of competence and satisfaction in the physical self and four sub-domains that are perceived physical endurance, perceived competence in sports, perceived physical force and perceived physical appearance, are performed. assessment of depressive symptomatology is also realised including momentary levels of depression, anxiety, rumination, efficacy of coping strategies and quality of life. secondary outcomes: assessment of postural control

Eligibility criteria:
inclusion criteria: * speaking french * aged between 18 and 65 years * diagnosed with current major depressive disorder * bdi ii score ≥ 12 * ipaq score \<600 exclusion criteria: * alcohol or substance(s) dependence(s) * psychotic disorders * anti-social personality * pregnant or nursing women * physical inability to perform active walking

Keywords: major depressive disorder follow-up study ecological momentary assessment physical activity depression self-esteem anxiety rumination quality of life
optimizing psoriasis treatment of etanercept combined methotrexate

Conditions: Psoriasis

Summary: the purpose of this study is to evaluate whether etanercept combined with methotrexate are superiority than etanercept as monotherapy in the treatment of chinese severe plaque psoriasis. a phase iv, multicenter, randomized, double-blind, controlled trial was conducted.the primary outcome was change from baseline in plaque psoriasis as assessed by pasi (psoriasis area and severity index) response or pasi75 (a patient that has an improvement from baseline pasi of at least 75%)


Eligibility criteria:
inclusion criteria: * adults of both sexes, at least 18 years of age * have stable plaque psoriasis for at least 6 months, psoriasis involving at least 10 percent of the body surface area, had a minimal pasi of 10 at screening * had previously received phototherapy or systemic psoriasis therapy at least once or candidates for such therapy in the opinion of the investigator exclusion criteria: * patients with guttate, erythrodermic, or pustular psoriasis at the time of screening * recent infection or opportunistic infections, active tuberculosis, hepatitis b and so on * liver and kidney dysfunction * those with other serious, progressive, uncontrolled disorders of vital organs and systems (including cardiovascular, liver, lung and kidney), other autoimmune diseases, cancer, hiv infection, which are not suitable for participation in the study of the disease * history of significant methotrexate toxicity or total cumulative methotrexate exposure \> 1000 mg (unless grade ‡ iiib liver injury has not occurred) * use of ultraviolet (uv) b therapy, topical ciclosporin or calcineurin inhibitors, class iii through vii topical corticosteroids (permitted on the scalp, axillae, and ⁄or groin), or topical vitamin a or d analogues within 14 days of screening * and psoralen or uva therapy, systemic psoriasis therapy (including methotrexate), oral retinoids, class i or ii topical corticosteroids, dithranol, cyclophosphamide, sulfasalazine, or intravenous or oral calcineurin inhibitors within 28 days of screening * patients were excluded if they had received a tumor necrosis factor (tnf) blocking agent or other biologics within 3 months or interleukin (il)-12 or il-23 inhibitors within 6 months of study initiation